Indication for neutralizing monoclonal antibodies for treatment of COVID-19 in real life: the big gap with controlled randomized trials
Revue Medicale de Bruxelles
; 43(5):538-540, 2022.
Article
in French
| EMBASE | ID: covidwho-2241456
ABSTRACT
Anti-SARS-CoV-2 neutralizing monoclonal antibodies treatments have been studied through randomized controlled trials and have demonstrated efficacy for prevention and early COVID-19 treatment. Their use in real life is different from studies in many points. Variant changes, vaccination coverage, treated groups with nAbs which are different from clinical trials are topics discussed in this paper.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
/
Randomized controlled trials
Language:
French
Journal:
Revue Medicale de Bruxelles
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS